Genentech Newswire

Comprehensive Real-Time News Feed for Genentech.

Results 1 - 20 of 371 in Genentech

  1. Obviousness, common general knowledge and expectations of success: Leo gets a maulingRead the original story w/Photo

    5 hrs ago | IPKat

    ... each test would have been difficult to predict, and yet the compound was found to be obvious. In Hospira UK Ltd v Genentech Inc [2014] EWHC 1094 (Pat) , noted by the IPKat here , Birss J had to deal with inventive step of an 'incremental' invention, ...

    Comment?

  2. Genentech inks potential $1 billion deal with NewLink GeneticsRead the original story w/Photo

    14 hrs ago | Seattle Post-Intelligencer

    NewLink Genetics' stock soared Monday on the announcement that it could earn $1 billion through a newly inked deal with Genentech to develop cancer immunotherapies. NewLink's name has been in the news lately because the Iowa company holds the commercial license for an Ebola vaccine developed by the Canadian government.

    Comment?

  3. Genentech pays $150M upfront in cancer 'checkpoint' drug dealRead the original story w/Photo

    19 hrs ago | Business Journal

    Genentech Inc. will pay $150 million upfront to NewLink Genetics in a potential $1 billion drug-development deal that could block two cancer pathways. At the center of the deal is Ames, Iowa-based NewLink's drugs that block what is known as the IDO pathway.

    Comment?

  4. US futures lower as weak IBM profits weighRead the original story w/Photo

    22 hrs ago | Iol.co.za

    ... and boosted its quarterly dividend. The company said it entered a licensing agreement with Roche Holding AG unit Genentech to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone ...

    Comment?

  5. Us Stocks-Futures lower as weak Ibm earnings weighRead the original story

    Yesterday | Reuters

    ... to $37.96 before the opening bell. The company said it entered a licensing agreement with Roche Holding AG unit Genentech to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone ...

    Comment?

  6. UPDATE 1-NewLink in $1 bln deal with Roche to develop cancer drugRead the original story

    Yesterday | Reuters

    NewLink Genetics Corp said it entered into an agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments. Iowa-based NewLink, which holds the commercial license for an Ebola vaccine developed by the Canadian government, will receive an upfront payment of $150 million under the worldwide licensing deal from Genentech, a unit of Switzerland's Roche.

    Comment?

  7. New front in war on Alzheimer's and other protein-linked brain diseasesRead the original story w/Photo

    Yesterday | Medical News Today

    ... Baird and Peter M. Douglas and their colleagues at the University of Michigan, The Scripps Research Institute and Genentech Inc., published their results in the Oct. 17 issue of the journal Science. Cells put a lot of effort into preventing proteins ...

    Comment?

  8. New market study, "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2014", has been publishedRead the original story

    Sunday | PR-inside.com

    ... factors that drove them from pipeline Companies Mentioned in this Report: Vical Incorporated, GlaxoSmithKline plc, Genentech, Inc., Agenus, Inc., Biotest AG, Merck & Co., Inc., Astellas Pharma Inc., 4SC AG, Bionor Pharma ASA, Altor BioScience ...

    Comment?

  9. TiGenix Publishes Transparency Notification Pursuant To Article 14 Of The Law Of May 2, 2007Read the original story

    Friday Oct 17 | BioSpace

    October 17, 2014 - TiGenix NV publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions. It concerns a notification made by the related companies Roche Holding AG / Roche Finanz AG following the passive crossing below the 3% threshold on November 22, 2013 by the group as a whole .

    Comment?

  10. New Front in War on Alzheimer's, Other Protein-folding DiseasesRead the original story w/Photo

    Friday Oct 17 | Bioscience Technology

    ... Baird and Peter M. Douglas and their colleagues at the University of Michigan, The Scripps Research Institute and Genentech Inc., will publish their results in the journal Science . Cells put a lot of effort into preventing proteins- which are like ...

    Comment?

  11. IPO Preview: Xenon PharmaceuticalsRead the original story w/Photo

    Thursday Oct 16 | Seeking Alpha

    ... partners include Teva Pharmaceutical Industries, Ltd., or Teva (through its subsidiary, Ivax International GmbH), Genentech, Inc., or Genentech, and Merck & Co., Inc., or Merck (through its affiliate, Essex Chemie AG). XENE's pharmaceutical ...

    Comment?

  12. Roche sales up 2%, boosted by cancer drugsRead the original story w/Photo

    Thursday Oct 16 | MarketWatch

    ... drugs, complex therapies derived from living organisms. Many of those drugs were developed by California-based Genentech, a pioneer in biologic therapies that Roche acquired in 2009. Global sales of Herceptin, a core breast cancer drug that will ...

    Comment?

  13. Roche Lifted by Cancer DrugsRead the original story w/Photo

    Wednesday Oct 15 | Wall Street Journal

    Roche Holding AG on Thursday reported a nearly 2% jump in third-quarter sales as the pharmaceutical giant's cancer drugs continued to power its performance. Basel-based Roche said group sales in the quarter rose 1.8% to 11.78 billion Swiss francs from 11.57 billion francs in the same quarter a year earlier.

    Comment?

  14. Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014Read the original story

    Tuesday Oct 14 | Business Wire

    ... Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, ...

    Comment?

  15. Exelixis, Inc. To Release Third Quarter 2014 Financial Results On Tuesday, November 4, 2014Read the original story

    Tuesday Oct 14 | BioSpace

    ... Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, ...

    Comment?

  16. Telford: The FDA's Slow-Roll on New Generic DrugsRead the original story w/Photo

    Monday Oct 13 | National Review Online

    ... target of this well-financed fear-mongering. A New York Times exposA found that biotech giants Amgen and Genentech proposed bills that would restrict the ability of pharmacists to substitute biosimilars for brand-name products. Biotech's ...

    Comment?

  17. Just Published: "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2014"Read the original story

    Sunday Oct 12 | PR-inside.com

    ... GmbH, F. Hoffmann-La Roche Ltd., Amgen Inc., Sanofi, AstraZeneca PLC, GlaxoSmithKline plc, Seattle Genetics, Inc., Genentech, Inc., MedImmune, LLC, Gilead Sciences, Inc., Merck & Co., Inc., Infinity Pharmaceuticals, Inc., Celltrion, Inc., Millennium ...

    Comment?

  18. "Refractory Multiple Myeloma - Pipeline Review, H2 2014" is now available at Fast Market ResearchRead the original story

    Saturday Oct 11 | PR-inside.com

    ... Company, Johnson & Johnson, Kyowa Hakko Kirin Co., Ltd., Sanofi, Eli Lilly and Company, GlaxoSmithKline plc, Genentech, Inc., Piramal Enterprises Limited, Prolexys Pharmaceuticals, Inc., ZIOPHARM Oncology, Inc., Millennium Pharmaceuticals, Inc., ...

    Comment?

  19. Solazyme Announces Appointment of Former DuPont CFO Gary Pfeiffer to the Board of DirectorsRead the original story

    Thursday Oct 9 | Business Wire

    ... members Michael Arbige, Vice President, Research and Development, DuPont Industrial Biosciences; Ian Clark, CEO of Genentech; James Craigie, Chairman and CEO of Church & Dwight Co.; Chairman Jerry Fiddler, former CEO and founder of Wind River ...

    Comment?

  20. Novartis AG Release: (Pr)Lucentis?? (ranibizumab) Approved By Health...Read the original story

    Wednesday Oct 8 | BioSpace

    ... around the world. For more information, please visit www.novartis.com . LucentisA is a registered trademark of Genentech Inc., used with permission by Novartis Pharmaceuticals Canada Inc. VisudyneA is a registered trademark of Novartis ...

    Comment?